Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.

Oncotarget - 11 Oct 2024

Ahmed Murtaza, Larson Brent K, Osipov Arsen, Azad Nilofer, Hendifar Andrew

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths, with adenosquamous carcinoma of the pancreas (ASCP), a rare variant, representing 1-10% of cases. Standard chemotherapy trials for pancreatic cancer exclude ASCP, leaving its optimal treatment uncertain. This report describes a 68-year-old male with metastatic ASCP and a KRAS G12C mutation, progressing through multiple lines of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Adenosquamous

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39392392
DOI: 10.18632/oncotarget.28659
PMCID: PMC11468600

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.PMID 39392392Read ↗

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.Semantic proximity Read ↗

Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.Semantic proximity Read ↗

Emerging Treatment Strategies in Pancreatic Cancer.Semantic proximity Read ↗

Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology.Semantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

New therapeutic targets in pancreatic cancer.Semantic proximity Read ↗

Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas.Semantic proximity Read ↗

Pancreatic acinar cell carcinoma: A comprehensive review.Semantic proximity Read ↗

Genomic signatures of pancreatic adenosquamous carcinoma (PASC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.